ATE342278T1 - Verfahren zur behandlung von diabetes mittels kgf - Google Patents

Verfahren zur behandlung von diabetes mittels kgf

Info

Publication number
ATE342278T1
ATE342278T1 AT95934808T AT95934808T ATE342278T1 AT E342278 T1 ATE342278 T1 AT E342278T1 AT 95934808 T AT95934808 T AT 95934808T AT 95934808 T AT95934808 T AT 95934808T AT E342278 T1 ATE342278 T1 AT E342278T1
Authority
AT
Austria
Prior art keywords
kgf
treating diabetes
mammals
pharmaceutical compositions
growth factor
Prior art date
Application number
AT95934808T
Other languages
English (en)
Inventor
Sharon Lea Aukerman
Glenn Francis Pierce
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE342278T1 publication Critical patent/ATE342278T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT95934808T 1994-10-13 1995-10-12 Verfahren zur behandlung von diabetes mittels kgf ATE342278T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32347594A 1994-10-13 1994-10-13
US32334094A 1994-10-13 1994-10-13
US48782595A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
ATE342278T1 true ATE342278T1 (de) 2006-11-15

Family

ID=27406268

Family Applications (2)

Application Number Title Priority Date Filing Date
AT95934793T ATE237633T1 (de) 1994-10-13 1995-10-12 Analogen des keratinozytenwachstumfaktors
AT95934808T ATE342278T1 (de) 1994-10-13 1995-10-12 Verfahren zur behandlung von diabetes mittels kgf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT95934793T ATE237633T1 (de) 1994-10-13 1995-10-12 Analogen des keratinozytenwachstumfaktors

Country Status (23)

Country Link
EP (2) EP0804479B1 (de)
JP (2) JP4216329B2 (de)
KR (1) KR100278597B1 (de)
CN (1) CN1168678A (de)
AT (2) ATE237633T1 (de)
AU (1) AU3707795A (de)
BG (2) BG101392A (de)
BR (2) BR9509269A (de)
CA (2) CA2202075C (de)
CZ (3) CZ297329B6 (de)
DE (2) DE69530403T2 (de)
DK (2) DK0804479T3 (de)
EE (2) EE9700225A (de)
ES (2) ES2196082T3 (de)
FI (2) FI971420L (de)
HU (2) HU226168B1 (de)
NO (2) NO971566L (de)
NZ (2) NZ505502A (de)
PL (2) PL320484A1 (de)
PT (2) PT785948E (de)
SI (2) SI0785948T1 (de)
SK (2) SK43197A3 (de)
WO (2) WO1996011950A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20022681B (en) 1989-01-31 2002-04-25 Aaronson Us Stuart A Protein KFG, Antibodies, Pharmaceutical Composition, Their Use, recombinant DNA, Cell, Method for Discoveries and Production of Proteins, Method for Stimulation of Epithelial Cells Growth
US7084119B2 (en) 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
BR9407035A (pt) 1993-06-29 1996-03-12 Chiron Corp Fragmento de fator de crescimento de queratinócitos conjugado composição terapêutica molécula de DNA vetor de expressão célula hospedeira processo para produzir fragmento de fator de crescimento de queratinócitos processo para cicatrização de ferimento e processo de tratamento de doença hiperproliferativa da epiderme
SI0785949T1 (en) * 1994-10-13 2003-08-31 Amgen Inc. Method for purifying keratinocyte growth factors
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
AU5410196A (en) * 1995-04-27 1996-11-18 Cooperatie Suiker Unie U.A. Inulin derivatives
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
DK0935652T3 (da) * 1996-10-15 2004-07-26 Amgen Inc Keratinocyt vækstfaktor-2 produkter
EP1473366A1 (de) * 1996-10-15 2004-11-03 Amgen Inc. Produkte des Keratinocyten-Wachstumsfaktors 2
CN1269805A (zh) 1997-07-14 2000-10-11 博尔德生物技术公司 生长激素和相关蛋白的衍生物
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
KR20010033484A (ko) 1997-12-22 2001-04-25 휴먼 게놈 사이언시즈, 인크. 각질세포 성장 인자-2 제제
US6242666B1 (en) * 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
JP2002534119A (ja) * 1999-01-14 2002-10-15 ボルダー バイオテクノロジー， インコーポレイテッド 自由システイン残基を有するタンパク質の生産方法
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6248725B1 (en) 1999-02-23 2001-06-19 Amgen, Inc. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction
US20040063634A1 (en) * 2001-01-19 2004-04-01 Carr Francis J. Modified kertinocyte growth factor (kgf) with reduced immunogenicity
AU2007214362B2 (en) * 2001-08-21 2009-11-26 Novartis Vaccines And Diagnostics, Inc. KGF polypeptide compositions
JP2005500390A (ja) 2001-08-21 2005-01-06 カイロン コーポレイション Ｋｇｆポリペプチド組成物
CA2589889C (en) 2004-12-15 2013-07-30 Amgen Inc. Therapeutic formulations of keratinocyte growth factor
CN102242124B (zh) * 2010-05-10 2013-05-22 齐鲁制药有限公司 改造的角化细胞生长因子基因及其在酵母中的表达
KR102440312B1 (ko) * 2020-08-28 2022-09-05 한국해양과학기술원 온도안정성을 향상시킨 fgf7 폴리펩타이드 및 그 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
JPH01137994A (ja) * 1987-08-10 1989-05-30 Shionogi & Co Ltd ｒｅｇ蛋白質
WO1990000877A1 (en) * 1988-07-27 1990-02-08 Marjan International Pty Ltd Carpet stretcher
GEP20022681B (en) * 1989-01-31 2002-04-25 Aaronson Us Stuart A Protein KFG, Antibodies, Pharmaceutical Composition, Their Use, recombinant DNA, Cell, Method for Discoveries and Production of Proteins, Method for Stimulation of Epithelial Cells Growth
JP3303211B2 (ja) * 1991-04-26 2002-07-15 武田薬品工業株式会社 ｂＦＧＦムテインおよびその製造法
JP3578761B2 (ja) * 1993-03-26 2004-10-20 アムジエン・インコーポレーテツド 表皮ケラチン細胞成長因子の治療目的での使用
US5348563A (en) * 1993-06-29 1994-09-20 Honeywell Inc. Air purifying apparatus
BR9407035A (pt) * 1993-06-29 1996-03-12 Chiron Corp Fragmento de fator de crescimento de queratinócitos conjugado composição terapêutica molécula de DNA vetor de expressão célula hospedeira processo para produzir fragmento de fator de crescimento de queratinócitos processo para cicatrização de ferimento e processo de tratamento de doença hiperproliferativa da epiderme
GB9315501D0 (en) * 1993-07-27 1993-09-08 Ici Plc Surfactant compositions
CA2168647A1 (en) * 1993-08-02 1995-02-09 Barbara A. Sosnowski Monogenous preparations of cytotoxic conjugates

Also Published As

Publication number Publication date
FI971536L (fi) 1997-06-09
NZ335109A (en) 2000-08-25
SI0804479T1 (sl) 2006-12-31
BG101408A (bg) 1997-12-30
JP4216329B2 (ja) 2009-01-28
CZ297328B6 (cs) 2006-11-15
CZ297329B6 (cs) 2006-11-15
SK284534B6 (sk) 2005-06-02
NO971566D0 (no) 1997-04-04
FI971536A0 (fi) 1997-04-11
BR9509329A (pt) 1997-10-14
ATE237633T1 (de) 2003-05-15
EP0785948A1 (de) 1997-07-30
NO971568D0 (no) 1997-04-04
EP0785948B1 (de) 2003-04-16
DK0785948T3 (da) 2003-08-04
CA2202075A1 (en) 1996-04-25
BG101392A (en) 1997-10-31
PL319784A1 (en) 1997-08-18
HU226168B1 (en) 2008-05-28
FI971420A0 (fi) 1997-04-04
WO1996011950A1 (en) 1996-04-25
CN1168678A (zh) 1997-12-24
PT785948E (pt) 2003-09-30
SK43197A3 (en) 1999-03-12
BR9509269A (pt) 1997-12-23
CA2202075C (en) 2003-12-09
NO318761B1 (no) 2005-05-02
DE69530403T2 (de) 2003-10-30
KR100278597B1 (ko) 2001-01-15
AU681546B2 (en) 1997-08-28
SI0785948T1 (en) 2003-08-31
JPH10507193A (ja) 1998-07-14
NO971566L (no) 1997-04-14
DE69530403D1 (de) 2003-05-22
ES2273338T3 (es) 2007-05-01
CA2201940C (en) 2009-05-12
AU3708395A (en) 1996-05-06
AU3707795A (en) 1996-05-06
FI971420A7 (fi) 1997-04-04
PT804479E (pt) 2007-02-28
CA2201940A1 (en) 1996-04-25
HUT78058A (hu) 1999-07-28
FI120040B (fi) 2009-06-15
JPH10507080A (ja) 1998-07-14
PL182888B1 (pl) 2002-03-29
NZ505502A (en) 2005-01-28
EP0804479A1 (de) 1997-11-05
NO971568L (no) 1997-06-12
EE9700081A (et) 1997-10-15
CZ98197A3 (cs) 1998-11-11
HUT78050A (hu) 1999-07-28
FI971420L (fi) 1997-04-04
ES2196082T3 (es) 2003-12-16
EE9700225A (et) 1998-02-16
DE69535264T2 (de) 2007-02-01
BG63167B1 (bg) 2001-05-31
WO1996011949A2 (en) 1996-04-25
EP0804479B1 (de) 2006-10-11
CZ105097A3 (cs) 1998-10-14
DE69535264D1 (de) 2006-11-23
JP4426646B2 (ja) 2010-03-03
DK0804479T3 (da) 2007-01-29
WO1996011949A3 (en) 1996-12-12
PL320484A1 (en) 1997-09-29
EE03975B1 (et) 2003-02-17
SK45597A3 (en) 1999-02-11

Similar Documents

Publication Publication Date Title
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
DE69523074D1 (de) Verfahren zur behandlung von implantierbaren biologischen geweben zur verringerung von verkalkung
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
DE69726289D1 (de) Verfahren und zusammensetzung zur behandlung von substraten bezüglich benetzbarkeit
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ATE190843T1 (de) Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE69621447D1 (de) Verwendung von nitroflavonoide zur behandlung von angstzuständen
DE60015791D1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE234614T1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
EP0909172A4 (de) Verfahren und zusammensetzungen zur behandlung von harninkontinenz unter verwendung von enantiomer-angereichertem (r,s)-glycopyrrolat
DE69535263D1 (de) Angiotensin ii zur verbesserung der befruchtung
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
EP1009421A4 (de) Verfahren und zusammenstellungen zur verbesserten wundheilung
ATE218877T1 (de) Bowman-birk-inhibitorzusammensetzungen zur behandlung von entzündungskrankheiten
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE189388T1 (de) Biologisch aktive ureido-derivate nützlich zur behandlung von multipler sklerose
DE69433851D1 (de) Tiermodell zum testen von arzneistoffen zur behandlung von leukämie oder hiv
DE69726037D1 (de) Zusammensetzung und Verfahren zur Behandlung von Kulturen gegen Bodenparasitärkomplexe

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0804479

Country of ref document: EP

EEIH Change in the person of patent owner